Clinical Trial

Guanfacine for Alcohol Use Disorder (AUD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-10-03; most recent amendment 2026-05-07.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT06629259
Lead Sponsor Indiana University
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions Alcohol Use Disorder
Enrollment 200 participants
Start Date 2025-10-03
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-09-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-11